Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 119Carcinoma, Hepatocellular 69Ovarian Neoplasms 62Neoplasms 36Carcinoma, Non-Small-Cell Lung 34Fallopian Tube Neoplasms 29Brain Neoplasms 24Glioblastoma 22Colonic Neoplasms 21Breast Neoplasms 19Neoplasm Metastasis 18Endometrial Neoplasms 18Stomach Neoplasms 15Uterine Cervical Neoplasms 14Rectal Neoplasms 14Lung Neoplasms 14Liver Neoplasms 11Triple Negative Breast Neoplasms 10Melanoma 8Glioma 8Carcinoma, Renal Cell 8Carcinoma, Ovarian Epithelial 8Biliary Tract Neoplasms 8Colorectal Cancer Metastatic 7Squamous Cell Carcinoma of Head and Neck 6Recurrence 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Gastrointestinal Neoplasms 6Advanced Solid Tumors 6Small Cell Lung Carcinoma 5

Interventions

Docetaxel 2Cisplatin 2130-nm albumin-bound paclitaxel 2taxane 1pembrolizumab 1liposomal doxorubicin 1durvalumab 1cemiplimab 1atezolizumab 1Pemetrexed 1Paclitaxel 1Nivolumab 1Granulocyte-Macrophage Colony-Stimulating Factor 1Biosimilar Pharmaceuticals 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaccinia × Bevacizumab × 1 year × Clear all
NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡